Herpes Zoster as a sign of AIDS and nonadherence to antiretroviral therapy: a case report by Reis, Helena Lucia Barroso dos et al.
CASE REPORT
Herpes Zoster as a Sign of AIDS and nonadherence to
antiretroviral therapy: a case report
Helena Lucia Barroso dos Reis,I Fernanda Sampaio Cavalcante,II Katia Regina Netto dos Santos,II Mauro
Romero Leal Passos,III Dennis de Carvalho FerreiraII
I Federal University of Espı´rito Santo (UFES), Gynecology and Obstetrics Department, Espı´rito Santo, Vito´ria/ES, Brazil. II Federal University of Rio de
Janeiro, Paulo de Go´es Microbiology Institute, UFRJ. IIIMicrobiology Institute, Rio de Janeiro/RJ, Brazil, Fluminense Federal University (UFF), STD Sector,
Nitero´i/RJ, Brazil.
Email: hbarroso@unimedvitoria.com.br
Tel.: 55 27 3335-7180
INTRODUCTION
The reactivation of varicella-zoster virus (VZV) infection
may occur during the course of human immunodeficiency
virus (HIV) infection as an initial indicator of the disease.
Post-herpetic neuralgia and multiple vesiculobullous lesions
have been described in HIV-infected patients with herpes
zoster.1,2 Nonadherence to highly active antiretroviral
therapy (HAART) has a significant impact on the patient’s
quality of life and increases the risk of mortality.3 We report
a case of an HIV-infected patient who developed herpes
zoster due to nonadherence to HAART.
CASE DESCRIPTION
A 55-year-old female patient of afro-descendant was
diagnosed with AIDS in 1999, when she developed chronic
diarrhea and weight loss. This patient was a homemaker
born in Bahia and residing in Serra-ES (Brazil) with an HIV-
positive and nonexclusive sexual partner and three children.
She had been in menopause for six years at the time of VZV
diagnosis. Antiretroviral treatment was initiated with
zidovudine (AZT) + didanosine in 2001 because her CD4+
count fell below 350 cells/mm3. Because of noncompliance,
she remained without anti-retroviral medication for 31
months, which, in 2008, allowed her to be susceptible to a
very aggressive clinical episode of herpes zoster with severe
neuralgia, which led to a seven-day hospitalization. Initially,
she presented with maculopapular lesions that progressed
into vesicles and then pustules and crusts on the right
thoracic region following the nerve path (Figure 1 and
Figure 2) that lasted for 12 days. Laboratory tests showed a
normal complete blood count (CBC), a viral load (VL) of
27,500 copies/mL and a CD4+ T lymphocyte count of 328
cells/mm3.
The patient was treated with intravenous acyclovir for
seven days, with marked improvement of the lesions. She
started therapy with AZT + lamivudine + abacavir. At the
same time, the cervical oncotic cytology was suggestive of
cervical intraepithelial neoplasia I (CIN I) and infection with
human papillomavirus (HPV). Colposcopy suggested CIN I,
and the cytological samples from the cervix after 3, 6, 12,
and 18 months were normal. A hypochromic scar remained
in the affected area after the herpes zoster was treated
(Figures 3A and B), which caused constraints on the
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Figure 1 - Grouped erythematous vesiculous and crusted herpes
zoster lesions on the right thoracic region along the intercostal
nerve path.
Figure 2 - Grouped erythematous vesiculous and crusted herpes
zoster lesions on the right thoracic region along the intercostal
nerve path – back view.
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patient’s social life and affected her quality of life.
Moreover, she suffered from persistent post-herpetic neur-
itis that lasted for 12 months. The patient remains in a
clinical follow-up program in the infectious and parasitic
diseases sector at a public hospital in Espı´rito Santo state.
Currently, the patient adheres correctly to the antiretroviral
therapy and has had no relapses of herpes zoster, and her
quality of life has improved significantly.
Above, we described an aggressive form of infection
caused by VZV that served as a warning flag for AIDS in a
patient who did not adhere to HAART.
The next section describes the factors involved in
noncompliance and provides support for a more effective
approach to the clinical follow-up of individuals with HIV.
DISCUSSION
Patients who meet the definition of AIDS, such as the patient
described in this report, exhibit significant inhibition of the
immune system and are susceptible to new bacterial, fungal,
and viral infections and to the reactivation of prior infections.
Some of these infections are considered AIDS defining and can
be categorized as opportunistic infections (OI).4
Some viral agents, especially herpesviruses, can cause
acute and persistent lytic infections, signaling immuno-
suppression in an early symptomatic phase of AIDS.
Among these, VZV stands out as one viral agent that can
be reactivated by the HIV-positive patient’s immunologi-
cal changes,5 manifesting clinically as vesicles that break
down into ulcers following the nerve path and as pre- and
post-injury neuralgia associated with intense pain. All of
these events, associated with the immunosuppression,
occurred were experienced by the patient described in this
report.
The current literature indicates that noncompliance is the
largest cause of failure of highly active antiretroviral
therapy (HAART). HAART must be understood as an
action in which the patient not only follows medical advice
but also understands and agrees to follow the guidelines
and requirements. Adherence to HAART includes following
schedules, maintaining proper dosage with no interruptions
(regardless of social life or travels) and even making use of a
balanced diet to support the therapy. Adverse effects or fear
of exposure may influence the patient’s motivation for not
adhering to the therapy, thereby jeopardizing the efficacy of
the recommended treatment and potentially impairing the
quality of life (Ferreira et al., 2011).6
Studies have identified different factors as causes of
patient noncompliance with antiretroviral treatment, includ-
ing fear of side effects, lack of adequate food, difficulty
integrating the treatment routine into their lives, forgetting
when to take the medicine, the influence of other people in
their social life, the amount of medicine to take and the
emotional state (Kaishusha Mupendwa et al., 2009).7
Other factors associated with noncompliance include age,
education, injecting drug use, alcohol use, drug regimens
with protease inhibitors, the presence of clinical signs and
symptoms, loss of companions, time of diagnosis of HIV
infection, a break in the continuity of care by one doctor or
hospital and depression (Glass et al., 2010).8 Two of these
issues are particularly notable: the ‘‘emotional state’’ and
depression. The patient in this report was depressed and
exhibited an altered emotional state, which were considered
possible causes for her refusal to use the proposed
antiretroviral therapy. The patient, at present, is on
HAART therapy and antidepressants in outpatient care.
Adherence measures are currently being reassessed
because of flaws in their evaluation standards (Zijenah,
2006; Bangsberg 2002).9,10 The search for a better quality of
life for HIV-infected individuals should be the central aim
when following this clinical group. This goal includes good
doctor-patient communication, respect for the specifics of the
infection and the life dynamics of each individual, support
from a multidisciplinary team, and a continual, active search
for these patients, if necessary, to increase adherence.
In conclusion, increasing adherence to HAART plays an
important role in reducing opportunistic infections, such
as VZV, and in improving the patient’s life by reducing
mortality.
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